Roche’s Basel Drug Substance site celebrates becoming the first Swiss recipient of the World Economic Forum (WEF) Global Lighthouse Award, recognising our leadership in implementing Digital & AI technologies.
Announced by the WEF on October 8, Roche’s Basel Drug Substance site has been designated a
We are thrilled that our efforts have led to us receiving the WEF Global Lighthouse site award. This is testament to our unwavering commitment to investment, sustainability, and digital transformation. Deploying Digital and AI solutions is critical to achieving our ambition of delivering 20 transformative medicines to patients over the next decade. A huge thanks to the Digital , AI & OE communities (PTE), PTx functions, IIX, Basel Drug Substance site and local colleagues from the site organization,– who have made this fantastic achievement possible and are enabling faster delivery of our treatments to patients at lower costs to society
Focus. Team Work. Persistence. To deliver our bold ambition of developing 20 new transformative medicines by the end of the decade, we knew we had to make some significant investments in our infrastructure. Understanding our end-to-end processes, and the complexity of developing and manufacturing new medicines required a fresh approach, and the integration of cutting-edge technology and innovation was required.
Over the past three years, our teams have worked tirelessly to modernize our technical footprint and deploy AI and digital technologies across our network, an achievement we are immensely proud of. By augmenting and transforming our digital approach, we’ve been able to significantly speed up time-to-market for new drugs as well as optimize costs.
Data & AI are fundamental to transforming the way we develop, manufacture & supply medicines and to ensuring that we are ’Doing now what patients need next’, By radically simplifying and automating our processes, augmenting our teams’ skill sets to create innovative insights, enhancing our products, and re-thinking our tech infrastructure to be more modular and composable, we are creating transformative treatments and value for patients and society. I’d like to express my heartfelt gratitude to the Digital , AI & OE communities (PTE), PTx functions, IIX, Basel Drug Substance site and local colleagues from the site organization for this fantastic achievement.
Our Basel Drug Substance site is the innovation hub for our global network, having set a new standard for excellence in the industry. It has one of the most complex manufacturing landscapes across our network, producing mono- and bispecific monoclonal antibodies, antibody drug conjugates and chemically synthesized small molecules. We are honored to receive the Global Lighthouse accolade.
This is just the start. These advancements have positioned us as a leader in the industry and will continue to set the stage for future success, with patients remaining at the heart of everything we strive to achieve. Our Basel site showcases the shift we’ve made having created a network-oriented culture and embedding digitally enhanced capabilities across our diverse workforce. Our achievements and learnings will play a pivotal role in scaling solutions across our global network.
To read more about the WEF’s Global Lighthouse Award, click